Necdet Üskent Selected Research

Trastuzumab (Herceptin)

6/2022	Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group.
10/2021	Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Necdet Üskent Research Topics

Disease

2	Breast Neoplasms (Breast Cancer) 02/2024 - 01/2020
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2023 - 01/2022
2	Stomach Neoplasms (Stomach Cancer) 06/2022 - 10/2021
2	Adenocarcinoma 06/2022 - 10/2021
1	Neoplasms (Cancer) 07/2023
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2022
1	Disease Progression 06/2022

Drug/Important Bio-Agent (IBA)

2	Hormones (Hormone)IBA 02/2024 - 01/2020
2	palbociclibIBA 02/2024 - 01/2020
2	alectinibIBA 07/2023 - 01/2022
2	Trastuzumab (Herceptin)FDA Link 06/2022 - 10/2021
1	ribociclibIBA 02/2024
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 02/2024
1	ErbB Receptors (EGF Receptor)IBA 02/2024
1	CrizotinibIBA 07/2023
1	atezolizumabIBA 12/2022
1	Cisplatin (Platino)FDA LinkGeneric 06/2022
1	Tyrosine Kinase InhibitorsIBA 01/2022
1	taxaneIBA 10/2021
1	Estrogen ReceptorsIBA 01/2020

Therapy/Procedure

4	Drug Therapy (Chemotherapy) 12/2022 - 10/2021
1	Therapeutics 10/2021